Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group.
about
Ultrasound-based elastography for the diagnosis of portal hypertension in cirrhotics.Ultrasound in chronic liver disease.Liver elastography, comments on EFSUMB elastography guidelines 2013.Ultrasonic elastography in clinical quantitative assessment of fatty liver.Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infectionLiver biopsy for histological assessment: The case against.Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C.Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis CPrediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.Comparison of the liver stiffness measurement by transient elastography with the liver biopsy.Assessment of liver fibrosis: noninvasive means.Early to Phase II drugs currently under investigation for the treatment of liver fibrosis.Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment.Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.Does low-dose prolonged steroid therapy affect the natural history of chronic hepatitis C?Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease.Real-time tissue elastography (RTE) for noninvasive evaluation of fibrosis in liver diseases in children in comparison to liver biopsy.Beyond scoring: a modern interpretation of disease progression in chronic liver disease.Fibroscan: a new noninvasive method for evaluation of liver dysfunction in Turner syndrome.
P2860
Q26778038-0C028D88-1976-4A0E-9379-D6D6C0B355DAQ30432218-C6467961-0CEB-475F-BCCC-0D4B69B5D9B5Q30448132-4D066589-E8B9-47C5-8573-3FFF44D72BB0Q30479169-9EF27FB7-30E6-460F-90AC-3825C5DA61EFQ33904205-B66F57C6-ABC6-4FAE-B7CC-38A4B026A6E1Q34469006-01F33B20-C1B5-4164-898C-EDD217FE5CEEQ34476310-62E1AADC-8802-4A00-A282-7723C11A9BC1Q35810531-1F72C4A2-6BC7-42D8-864E-98B0B1315FBBQ37002423-D5E630EB-02CF-46F7-9452-4E7FDCAF0C50Q37411941-47B1ECAE-D940-43C3-B85E-DE5F86958EBFQ37536973-984B92F1-9EEA-43EC-B2AC-B55D9D6AD556Q38303313-B52D572C-F00B-4B53-BD8B-8D13B7A65D90Q40126822-F206648A-0CF2-403A-80B8-0368570BABEBQ40913201-F2B6F05D-7BF6-4BF0-8816-8FAF30579716Q42239858-AF670CB5-46B9-4B4B-AEFB-9CEB970B2998Q46636339-FEC4E0CF-29C2-48B3-8358-EB959ACCD62FQ50221691-5B898286-21DE-4645-BE58-BD26A5774C7CQ51018265-A11593E1-B8DE-4F6E-B3B2-6847D2CDDCF4Q51645420-BB3A2539-8FC6-4C22-9948-440D8AAB9479
P2860
Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Fibrosis as an end point for c ...... international fibrosis group.
@ast
Fibrosis as an end point for c ...... international fibrosis group.
@en
type
label
Fibrosis as an end point for c ...... international fibrosis group.
@ast
Fibrosis as an end point for c ...... international fibrosis group.
@en
prefLabel
Fibrosis as an end point for c ...... international fibrosis group.
@ast
Fibrosis as an end point for c ...... international fibrosis group.
@en
P1476
Fibrosis as an end point for c ...... international fibrosis group.
@en
P2093
International Fibrosis Group Meeting Participants
John McHutchison
P304
P356
10.1016/J.CGH.2006.07.006
P407
P577
2006-09-18T00:00:00Z